Vikas Sinha
CIK 1337845 · Chief Financial Officer · last filed 2026-04-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$32.63M
Companies
3
Total Filings
162
Lifetime Open-Market Net
-$4.66M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SRRK | Chief Financial Officer | 619,856 | $52.64 | $32.63M | -$1.23M | 5 | 2026-04-20 |
| Verona Pharma plc (VRNA) Delisted | Director | 0 | $106.91 | $0 | -$3.18M | 12 | 2025-10-08 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | See Remarks | 774,118 | $9.81 | $7.59M | -$246.5K | 40 | 2025-02-24 |
Recent Filings · Page 5 of 17
162 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-03 | KLRS | Notice (144) | −4,957 | -$3.9K | EDGAR |
| 2024-04-30 | Verona Pharma plc (VRNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-23 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −3,378 | -$2.5K | EDGAR |
| 2024-04-22 | KLRS | Notice (144) | −1,857 | -$1.4K | EDGAR |
| 2024-04-19 | KLRS | Notice (144) | −1,521 | -$1.1K | EDGAR |
| 2024-04-04 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −885 | -$683 | EDGAR |
| 2024-04-02 | KLRS | Notice (144) | −885 | -$683 | EDGAR |
| 2024-02-22 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −2,893 | -$2.0K | EDGAR |
| 2024-02-20 | KLRS | Notice (144) | −2,893 | -$2.0K | EDGAR |
| 2024-02-06 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −18,331 | -$12.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.